Press Releases

John Bell & Croyden – established in 1798 and pharmacists to Her Majesty the Queen since 1958 – has been chosen by NHS England as a Covid-19 vaccination site. The pharmacy, which has kept its doors open through two world wars and now a pandemic, is the first McKesson UK community pharmacy to participate in the vaccine rollout. The flagship store in London’s Harley Street Medical Area will help support the Government’s nationwide Covid-19 vaccination progr

SML Genetree announced that it has obtained approval from the US Food and Drug Administration for the emergency use of its Ezplex SARS-CoV-2 G test kit. These are molecular diagnostic tests. for the qualitative detection of SARS-CoV-2 RNA from nasopharyngeal and oropharyngeal swabs and mucus specimens, and may also be used for testing in pooled patient specimens containing up to 5 upper respiratory swab specimens. Samples will be taken by healthcare providers into ampoules containing transpor

EMA has received an application for conditional marketing authorisation (CMA) for a COVID-19 vaccine developed by AstraZeneca and Oxford University. The assessment of the vaccine, known as COVID-19 Vaccine AstraZeneca, will proceed under an accelerated timeline. An opinion on the marketing authorisation could be issued by 29 January during the meeting of EMA’s scientific committee for human medicines (CHMP), provided that the data submitted on the quality, safety and efficacy of the vac

Precision Medicine Group announced the acquisition of Project Farma. It is a patient-focused company in the field of bioengineering services that supports innovators in the field of life sciences in creating and improving modern therapies. Project Farm enriches Precision with cutting-edge expertise in the production of life-changing drugs and its unique focus on the rapidly growing field of cell and gene therapy. The acquisition of Project Farm means making better use of the potential of end-

BONE THERAPEUTICS, the cell therapy company addressing unmet medical needs in orthopedics and other diseases, and Rigenerand SRL, the biotech company that both develops and manufactures medicinal products for cell therapy applications, primarily for regenerative medicine and oncology, today announce the signing of a first agreement for a process development partnership. “Allogeneic mesenchymal stem cell (MSC) therapies are currently being developed at an incredible pace and ar

Travere Therapeutics, Inc announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD). Sparsentan is an investigational product candidate currently being evaluated for the treatment of IgAN, as well as focal segmental glomerulosclerosis (FSGS) in pivotal Phase 3 clinical trials that are expected to report topline data from

Capricor Therapeutics,, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza announced that the companies have entered into an agreement for the development of CAP-1002, its leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.

Byondis, a clinical-stage biopharmaceutical company today announced that its Chief Executive Officer, Marco Timmers, Ph.D., will present at the J.P. Morgan Healthcare Conference at 07:30 AM EST / 01:30 PM Central European Time (CET) on Thursday, January 14, 2021.  A link to the live audio webcast of this presentation will be available on the Events Calendar of www.byondis.com. A replay will also be available on the Byondis website following the presentation. About Byond

Leukocare AG, a German biotechnology company specialized in formulation development for biologics, viral vectors and vaccines, today announced the opening of its development laboratories and offices in Milford, MA, USA. The recently incorporated Leukocare Inc., a wholly owned subsidiary of Leukocare AG, lays the foundation for supporting US based clients on site and further strengthens Leukocare´s position as a leading provider of biopharmaceutical formulation development services. Leuk

Resolution Bioscience, Inc. announced a companion diagnostic agreement with Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company. As part of the agreement, Resolution’s ctDx™ liquid biopsy technology will be used to help identify non-small cell lung cancer (NSCLC) patients who may benefit from Mirati’s investigational KRAS G12C inhibitor therapy. The fast and non-invasive assay was designed to detect actionable NSCLC mutations, such as KRAS G1